KR20250021652A - 생체내 수용체 점유율을 결정하기 위한 검정 - Google Patents

생체내 수용체 점유율을 결정하기 위한 검정 Download PDF

Info

Publication number
KR20250021652A
KR20250021652A KR1020257003448A KR20257003448A KR20250021652A KR 20250021652 A KR20250021652 A KR 20250021652A KR 1020257003448 A KR1020257003448 A KR 1020257003448A KR 20257003448 A KR20257003448 A KR 20257003448A KR 20250021652 A KR20250021652 A KR 20250021652A
Authority
KR
South Korea
Prior art keywords
btk
leu
glu
lys
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257003448A
Other languages
English (en)
Korean (ko)
Inventor
나이유 젱
이안 맥쿼리 캐틀렛
지아닝 젱
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20250021652A publication Critical patent/KR20250021652A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
KR1020257003448A 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정 Pending KR20250021652A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862669442P 2018-05-10 2018-05-10
US62/669,442 2018-05-10
PCT/US2019/031524 WO2019217684A1 (en) 2018-05-10 2019-05-09 Assay to determine in vivo receptor occupancy
KR1020207035120A KR102764357B1 (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035120A Division KR102764357B1 (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Publications (1)

Publication Number Publication Date
KR20250021652A true KR20250021652A (ko) 2025-02-13

Family

ID=66821369

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257003448A Pending KR20250021652A (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정
KR1020207035120A Active KR102764357B1 (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207035120A Active KR102764357B1 (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Country Status (7)

Country Link
US (2) US12085564B2 (enExample)
EP (1) EP3791183B1 (enExample)
JP (2) JP7570925B2 (enExample)
KR (2) KR20250021652A (enExample)
CN (2) CN113804873B (enExample)
ES (1) ES2992942T3 (enExample)
WO (1) WO2019217684A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021652A (ko) 2018-05-10 2025-02-13 브리스톨-마이어스 스큅 컴퍼니 생체내 수용체 점유율을 결정하기 위한 검정
CN115932261B (zh) * 2022-08-15 2025-07-25 广州医科大学附属第五医院 一种btk受体占有率的检测方法
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源（北京）药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
WO2012010240A1 (en) * 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP3033625B1 (en) * 2013-08-13 2020-01-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
KR20250021652A (ko) 2018-05-10 2025-02-13 브리스톨-마이어스 스큅 컴퍼니 생체내 수용체 점유율을 결정하기 위한 검정

Also Published As

Publication number Publication date
US12085564B2 (en) 2024-09-10
CN113804873B (zh) 2024-06-18
ES2992942T3 (en) 2024-12-20
JP7570925B2 (ja) 2024-10-22
KR20210008028A (ko) 2021-01-20
KR102764357B1 (ko) 2025-02-10
WO2019217684A1 (en) 2019-11-14
CN112105930A (zh) 2020-12-18
EP3791183A1 (en) 2021-03-17
EP3791183B1 (en) 2024-07-24
JP2021523367A (ja) 2021-09-02
CN112105930B (zh) 2025-02-28
US20210156854A1 (en) 2021-05-27
JP2025011208A (ja) 2025-01-23
US20250085279A1 (en) 2025-03-13
CN113804873A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
US20250085279A1 (en) Assay to determine in vivo receptor occupancy
Kulyyassov et al. Targeted liquid chromatography‐tandem mass spectrometry analysis of proteins: basic principles, applications, and perspectives
Percy et al. Comparison of standard-and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins
Cox et al. Multiple reaction monitoring as a method for identifying protein posttranslational modifications
Whiteaker et al. Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry
Faria et al. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC–MS/MS
Ocaña et al. An immunoaffinity liquid chromatography–tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum
Wu et al. A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water‐miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection
CA2732109A1 (en) Mass spectrometry assay for plasma-renin
Zhang et al. Immunoaffinity LC–MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker
Li et al. Peptide and protein quantification using automated immuno-MALDI (iMALDI)
Huang et al. Identification and quantification of immunoglobulin G (G1, G2, G3 and G4) in human blood plasma by high-resolution quadrupole-Orbitrap mass spectrometry
Kim et al. Quantitative analysis of low-abundance serological proteins with peptide affinity-based enrichment and pseudo-multiple reaction monitoring by hybrid quadrupole time-of-flight mass spectrometry
Zhi et al. Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification
Grote et al. Using pure protein to build a multiple reaction monitoring mass spectrometry assay for targeted detection and quantitation
JP7629278B2 (ja) Ａβペプチドを測定するための抗体セット、Ａβペプチドの測定方法及び試薬キット
Chen et al. Sequential immunoaffinity-LC/MS assay for quantitation of a therapeutic protein in monkey plasma
Kuhn et al. Multiplexed immunoaffinity enrichment of peptides with anti-peptide antibodies and quantification by stable isotope dilution multiple reaction monitoring mass spectrometry
Dillen et al. A screening UHPLC–MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species
Geumann et al. A sandwich enzyme-linked immunosorbent assay for the quantification of insoluble membrane and scaffold proteins
Park et al. Qualification and application of a liquid chromatography–quadrupole time‐of‐flight mass spectrometric method for the determination of trastuzumab in rat plasma
Tao et al. High-throughput protein modification quantitation analysis using intact protein MRM and its application on hENGase inhibitor screening
Dahabiyeh et al. Measurement of the total angiotensinogen and its reduced and oxidised forms in human plasma using targeted LC-MS/MS
Mesmin et al. Mass spectrometric quantification of AcSDKP‐NH2 in human plasma and urine and comparison with an immunoassay
Anselm et al. Immunoaffinity-Based Liquid Chromatography Mass Spectrometric Assay to Accurately Quantify the Protein Concentration of HMGB1 in EDTA Plasma

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250203

Application number text: 1020207035120

Filing date: 20201207

PG1501 Laying open of application